Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark A. Voelker who wrote (883)	9/13/1998 2:41:00 PM
From: mesaone	of 1432

Mark, I am sure you won't mind my reprinting your analysis of the FDA's official response to the British Medical Journal's article on Albumin and how it can lead to increased fatalities among critical care patients. By proclaiming that albumin is high risk, the FDA is certainly going to be diligent about trying to approve a safe substitute to albumin. You and I have always been in agreement that the market size for Hextend is not limited to the hespan market, but includes the albumin market. In light of the FDA's cautionary notice to the medical community, I would hope that FDA approval for Hextend will be forth coming before the end of this year... and hopefully sooner. inch.com The complete article from the British Medical Journal and the FDA's dear doctor letters have been linked to my web site. I am a long biotime shareholder and am not employed by BioTime.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next